Home
Tillotts Pharma

Tillotts Pharma Market Share Analysis for November 2025

The Executive Committee consists of experienced professionals with extensive experience in the pharmaceutical industry. Learn more about each member here.

Health > Biotechnology and Pharmaceuticals

Domaintillotts.com

Year Founded1986

Employees201 - 500

Annual Revenue$100M - $200M

Tillotts Pharma

Tillotts Pharma (including company regionals)

tillotts.com

See more website traffic and engagement information

Tillotts Pharma Revenue up to November 2025 is 100M - 200M

revenue generated by Tillotts Pharma top domains

Tillotts Pharma top domains revenue over 3 years

Revenue for Tillotts Pharma top domains

tillotts.com100M - 200M

See more with Sales Intelligence

Total visits to Tillotts Pharma's top domains

Understand Tillotts Pharma market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

tillotts.com12.9K

See more with Sales Intelligence

Avg. visit duration in Tillotts Pharma's top domains

Analyze Tillotts Pharma engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

tillotts.com00:00:15

See more with Sales Intelligence

Avg. pageviews on Tillotts Pharma's top domains

See how Tillotts Pharma keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

tillotts.com2.02

See more with Sales Intelligence

Tillotts Pharma top competitors by domain

Top similar sites in November 2025, ranked by their affinity

myriad.comCompany NameMyriadEmployees1001 - 5000HQUnited States, Utah, Salt Lake CityAnnual revenue$500M - $1BTotal visits206.7KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Tillotts Pharma

These are the website technologies, by industry, used by Tillotts Pharma top domains

Widget (7)

Twemoji

Email Services (4)

Microsoft Exchange Online

Advertising (3)

DoubleClick

Content Management System (2)

WordPress

More Technologies

9

See all

News & Signals from Tillotts Pharma

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsTillotts Pharma AG launched Octasa 800 mg on Apr 6th '23."Earlier this year, Tillotts Pharma AG announced the launch of Octasa ® 800 mg, and Tillotts Pharma AG is delighted to continue its strong relationship with Tillotts by bringing Octasa ® 1600 mg to Canadian patients suffering from moderately active ulcerative colitis.

NewsTillotts Pharma AG launched Octasa 800mg delayed-release tablets on Oct 19th '22.Tillotts Pharma AG ("Tillotts"), part of the Japanese Zeria Group, is pleased to announce the recent launch of Octasa® 800mg (mesalazine) delayed-release tablets, as first-line treatment for moderately active ulcerative colitis (UC) in Canada.

NewsTillotts Pharma AG launched Asacol 800 mg tablets in China on Jul 1st '21.For instance, in July 2021, Tillotts Pharma AG launched Asacol 800 mg tablets in China for the treatment of mild to moderate ulcerative colitis.